Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: A single-center experience

Immune checkpoint inhibitors (ICIs) like cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA4) and programmed death cell protein 1 (anti-PD1) have revolutionized cancer treatment. As ICI use becomes widespread, more immune-related adverse events (irAE's) are being reported. Our aim was to in...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaur, Aneet, Doberstein, Taylor, Amberker, Rachana Ramesh, Garje, Rohan, Field, Elizabeth Hirak, Singh, Namrata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
6900
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6799752/
https://www.ncbi.nlm.nih.gov/pubmed/31593084
http://dx.doi.org/10.1097/MD.0000000000017348

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6799752/
https://www.ncbi.nlm.nih.gov/pubmed/31593084
http://dx.doi.org/10.1097/MD.0000000000017348

Ejemplares similares